Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.39 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.38 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26203829 | 1.00 | SPHK1 (0.39) | SPHK1SPHK2PLA2G2CALDH1A1USP2 | |
| SCHEMBL26203827 | 1.00 | SPHK1 (0.39) | SPHK1SPHK2PLA2G2CALDH1A1USP2 | |
| SCHEMBL2090432 | 0.82 | SPHK1 (0.42) | SPHK1SPHK2PLA2G2CALDH1A1USP2 | |
| SCHEMBL26724993 | 0.82 | PAOX (0.43) | SPHK1SPHK2PLA2G2CALDH1A1USP2 | |
| SCHEMBL10599228 | 0.82 | ALDH1A1 (0.55) | PLA2G2CALDH1A1TLR2 | |
| SCHEMBL10596601 | 0.82 | ALDH1A1 (0.55) | PLA2G2CALDH1A1TLR2 | |
| SCHEMBL18769026 | 0.82 | GAA (0.38) | ALDH1A1CES2HTTGAA | |
| SCHEMBL27056870 | 0.81 | KDM4C (0.39) | ALDH1A1HTTGAA | |
| SCHEMBL25029665 | 0.81 | CES2 (0.42) | CES2HTT | |
| SCHEMBL26201926 | 0.81 | TDP1 (0.38) | ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | SPHK1 3087/4885SPHK2 2390/4885PLA2G2C 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.